Pan-SIRT1–3 inhibitor NH4-6 and SIRT2-selective inhibitor NH4-13 (Figure 1) both suppressed tumor growth, but NH4-13 had lower toxicity and comparable efficacy in a breast cancer model [131]. The gene discussed is SIRT2; the disease is breast carcinoma.